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Characterization of Extensively Drug-Resistant Tuberculosis Cases
from Valle del Cauca, Colombia
Extensively drug-resistant tuberculosis (XDR-TB), which is TBresistant to isoniazid and rifampin plus one fluoroquinolone
and a second-line injectable drug, represents an obstacle for the
treatment and control of TB. Previously, we reported four
XDR-TB cases and a high proportion of the Beijing genotype
among multidrug-resistant TB (MDR-TB) isolates in the state of
Valle del Cauca, Colombia (3), where a MDR-TB hot spot had
been identified (7). According to the information of the local TB
program, to date 21 XDR-TB cases have been diagnosed in the
country, 14 of which were from this state.
With the approval of the Centro Internacional de Entrenamiento
e InvestigacionesMédicas (CIDEIM)ReviewBoard,wecharacterized
the XDR-TB cases detected in Valle del Cauca in the period 2001 to
2009, including their clinical and epidemiological features.
Resistance profiles were identified using the proportion method
on 7H10 agar (6) and confirmed by a supranational laboratory.Mo-
lecular characterization of the isolates was performed by spoligotyp-
ing (5) and24-locusvariable-number tandem-repeat (VNTR) typing
(8). GenoTypeMTBDRplus and -sl assays (Hain Lifescience GmbH)
were applied to identifymutations associated with resistance to first-
and second-line anti-TB drugs. Shared types and lineages of Myco-
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TABLE 1 Phylogenetic and epidemiological data of XDR-TB isolates from Valle del Cauca, Colombiam
a Spoligotypes are shown in octal format; lineages are designated according to the SITVIT2 database.
b MIT numbers represent mycobacterial interspersed repetitive unit (MIRU) international types determined using 24 loci. The 8 unique profiles are defined as MIT101, -45, and -46
and five different orphan patterns.
c Strains 03 and 04, which differ at a single MIRU locus (4 and 2 copies for MIRU-40, respectively), showed related spoligotype binary patterns SIT3010 and SIT881; hence, it is
possible that SIT881 evolved by loss of a single block of spacers 25 to 31 either directly from SIT3010 or from a linked ancestor.
d All the Beijing SIT190 strains (ID 06, 07, 08, 09, and 10) are highly related, since they represent a single locus variant in the 24-locus typing scheme (4, 3, 3, 3, and 2 copies for
MIRU-39, respectively).
e Diagnosed in 2001 but classified as an XDR-TB case until 2007 according to the WHO definition.
f S315T1: base exchange at codon 315, AGC to ACC.
g S315T2: base exchange at codon 315, AGC to ACA.
h For this isolate, there was no hybridization either in the WT2 probe which analyzed nucleic acid in the position 8 or in either of the two mutations described.
i This gene region is defined by the absence of WT7 probe which could represent any of these mutations: H526R, H526P, H526Q, H526N, H526L, H526S, and H526C.
j Isolate with an absence in the hybridization probes WT2 and WT2/WT3 that could have represented any of these mutations: Q513L, Q513P, and del514–516.
k Heteroresistant strain.
l Epidemiologically linked cases.
m Abbreviations: BCG,Mycobacterium bovis; bacillus Calmette-Guérin vaccination SIT, spoligotype international type; ID, identification number; Unk, unknown; NA, data not
available; M, male; F (in column 6), female; R, relapse; F (in column 7), failure of treatment with first-line drugs; N, new case; OT, on treatment; Neg, negative; Pos, positive; WT,
wild type. Numbers in column 6 represent age in years.
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bacterium tuberculosis isolates were determined using the SITVIT2
database (property of Institute Pasteur de la Guadeloupe).
In total, 10 XDR-TB patients were identified. Theirmedian age
was 30 years, and two cases (representing friends) were epidemi-
ologically linked. All patients suffered from either bilateral disease
or compromised lung function, and one underwent pneumonec-
tomy. Three patients were labeled as primary resistant cases as
they had no history of TB, suggesting active transmission of XDR-
TB. The remaining patients had been intermittently exposed to
second-line drugs. Six patients had a fatal outcome, one of them
being HIV positive (Table 1).
Shared types/lineages SIT190/Beijing, SIT62/H1, SIT881/un-
known, SIT545/LAM2, and SIT3010/S were identified by spoligo-
typing. These genotypes, combined with the VNTR 24-locus re-
sults, yielded eight unique profiles, with MIRU-39 being the only
locus that discriminated between the highly related Beijing/
SIT190 strains (Table 1). The Beijing genotype was the most fre-
quent (5/10), and one specific subtype, MIT45, was especially
present among younger patients (30 years old), new TB cases,
and fatal outcomes (Table 1).
Non-Beijing strains 03 and 04 differed only in a single locus
(MIRU-40) and also revealed the highly related spoligopatterns
SIT3010 and SIT881 (Table 1). It is conceivable either that SIT881
evolved directly from SIT3010 or that they both derived from a
common ancestor.
The distribution of the 5 XDR-TB shared types and lineages
identified by spoligotyping in this state compared to the world-
wide distribution revealed their high geographical specificity for
South America and for Colombia in particular (Table 2).
The most frequent mutations associated with resistance to isoni-
azid and rifampin were S315T1 (80%) and S531L (70%) in the katG
and rpoBgenes, respectively.Thesemutationswerepreviously shown
to be related to MDR-TB transmission in Europe (2). A1401G
(100%) and D94G (90%) were the most common mutations in the
rrs and gyrA genes, associated with resistance to aminoglycoside-cy-
clic peptides and fluoroquinolone, respectively (Table 1).
Mostof theXDR-TBpatientshadbeen treatedwithmoxifloxacin,
and all isolates had mutations in the gyrA gene; however, nine were
phenotypically susceptible to this drug; suggesting alternative muta-
tions or other resistance mechanisms. Moreover, one isolate (ID 03)
did not exhibit concordance between the phenotypic and genotypic
susceptibility profiles for isoniazid, emphasizing the importance of
phenotypic drug susceptibility testing as the basis for treatment.
The presence of the same mutations in the Beijing isolates, in
addition to the highly similar VNTR patterns, suggests the clonal
expansion of this particular Beijing lineage. Haarlem SIT62/H1
was the second most frequent (2/10) sublineage, as in previous
observations in Colombia (Table 2) (3). Multiple mutational
events and clonal expansion of one or more hypervirulent and
resistant strains (e.g., Beijing and Haarlem) may be occurring in
Valle del Cauca (1, 4).
The observed genetic relatedness between most of our
XDR-TB isolates (Table 1), as well as their high geographical spec-
ificity (Table 2), highlights the emergence of XDR-TB strains
within a pool of actively transmitted M. tuberculosis clinical iso-
lates, which is highly alarming. Moreover, despite continuous ef-
forts, a need remains to advance drug susceptibility testing and
individualized treatment availability, especially since these pa-
tients have a prolonged infectious stage, resulting in a greater dis-
semination of these strains.
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TABLE 2Worldwide distribution of theM. tuberculosis shared types (SIT) present among the 10 Colombian XDR-TB isolates as determined using
the SITVIT2 database
SIT (clade) octal no. (SITVIT2
database no.) Spoligotype
Distribution (%) in regions
with3% of a given
SIT(s)a
Distribution (%) in countries
with3% of a given SIT(s)b
SIT62 (H1) 777777774020731
(497)
▫▫▫▫▫▫▫▫▫▫▫ AMER-S 40.24, EURO-S
13.68, AMER-N 13.68,
EURO-W 8.05, AFRI-E
4.02, AFRI-W 3.62
COL 37.63, USA 13.68, ITA
8.25, ESP 4.22, FXX 3.62,
GMB 3.42
190 (Beijing)
000000000003731 (179)
▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫ ASIA-E 35.2, AMER-N
32.96, AMER-S 16.76,
ASIA-SE 5.59
USA 32.96, CHN 24.58, COL
16.2, JPN 6.7, KOR 3.35
545 (LAM2)
675737607760771 (8)
▫▫▫▫▫▫▫▫▫▫▫ AMER-S 50.0, EURO-W
25.0, AMER-N 25.0
COL 50.0, USA 25.0, FXX
25.0
881 (unknown)
776377770000731 (72)
▫▫▫▫▫▫▫▫▫▫▫▫▫▫▫ AMER-S 76.0, AMER-N
16.0, EURO-S 8.0
COL 72.0, USA 16.0, VEN
4.0, ITA 4.0, ESP 4.0
3010 (S) 776377777740731 (9) ▫▫▫▫▫▫▫▫ AMER-S 77.78, EURO-S
11.11, AMER-N 11.11
COL 66.67, USA 11.1, PER
11.1, ITA 11.1
a Worldwide distribution is reported for regions with SITs representing3% of their total number in the SITVIT2 database. The definition of macrogeographical regions and
subregions (http://unstats.un.org/unsd/methods/m49/m49regin.htm) is according to the United Nations. Regions: AFRI (Africa), AMER (Americas), ASIA (Asia), EURO (Europe),
and OCE (Oceania), subdivided into E (eastern), M (middle), C (central), N (northern), S (southern), SE (southeastern), and W (western). Furthermore, CARIB (the Caribbean)
belongs to the Americas, while Oceania is subdivided in 4 subregions, AUST (Australasia), MEL (Melanesia), MIC (Micronesia), and POLY (Polynesia). Note that in our
classification scheme, Russia has been assigned a new subregion by itself (northern Asia) instead of including it among the rest of eastern Europe. That assignment reflects its
geographical localization as well as due to the similarity of specific TB genotypes circulating in Russia (a majority of Beijing genotypes) to those prevalent in central, eastern, and
southeastern Asia.
b The 3-letter country codes are according to http://en.wikipedia.org./wiki/ISO_3166–1_alpha-3; countrywide distribution is shown only for SITs representing3% of their total
number in the SITVIT2 database.
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